Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

ERYTECH Pharma S.A. (ERYP)

0.591   0.041 (7.45%) 01-27 16:00
Open: 0.59 Pre. Close: 0.55
High: 0.641 Low: 0.52
Volume: 38,317 Market Cap: 21(M)

Technical analysis

as of: 2023-01-27 4:44:13 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.76     One year: 0.89
Support: Support1: 0.43    Support2: 0.3
Resistance: Resistance1: 0.65    Resistance2: 0.76
Pivot: 0.52
Moving Average: MA(5): 0.55     MA(20): 0.47
MA(100): 0.59     MA(250): 1.03
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 71.6     %D(3): 67.5
RSI: RSI(14): 61
52-week: High: 2.18  Low: 0.3
Average Vol(K): 3-Month: 40 (K)  10-Days: 26 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ERYP ] has closed below upper band by 22.7%. Bollinger Bands are 4.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.64 - 0.64 0.64 - 0.65
Low: 0.51 - 0.52 0.52 - 0.52
Close: 0.59 - 0.59 0.59 - 0.6

Company Description

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

Headline News

Fri, 27 Jan 2023
European Equities Move Lower Friday, Set to End Week in Negative Territory - Marketscreener.com

Tue, 24 Jan 2023
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are ... - Investing.com UK

Wed, 18 Jan 2023
Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading - Marketscreener.com

Wed, 11 Jan 2023
Erytech Pharma SA (ERYP) Stock Has Risen 38.89% This Week: Buy, Hold, or Sell? - InvestorsObserver

Wed, 12 Oct 2022
Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 ... - Markets Insider

Mon, 12 Sep 2022
ERYTECH Provides Business and Financial Update for the First Half ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 31 (M)
% Held by Insiders 2.826e+007 (%)
% Held by Institutions 0 (%)
Shares Short 46 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.932e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 943.2
Return on Equity (ttm) 0
Qtrly Rev. Growth 2.2e+006
Gross Profit (p.s.) -37.5
Sales Per Share 0
EBITDA (p.s.) 2.67949e+006
Qtrly Earnings Growth -1.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 1.28

Stock Dividends

Dividend 0
Forward Dividend 43220
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.